|Systematic (IUPAC) name|
|Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum|
|Routes||oral, suspension, rectal suspension|
|Bioavailability||3-5% (local acting)|
|Metabolism||GI; liver: unknown|
|Mol. mass||2086.75 g/mol|
|(what is this?)|
Sucralfate is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers. Brand names include Sucramal in Italy; Carafate in U.S.A.; Sucralcoat, Pepsigard, Sucral, Sucrafil, Hapifate in India; Sutra or Musin in parts of South-East Asia; Sulcrate in Canada; Ulsanic in South Africa and Israel; and Antepsin in Turkey. Sucralfate is also used for the treatment of gastroesophageal reflux disease (GERD) and stress ulcers. Unlike the other classes of medications used for treatment of peptic ulcers, sucralfate is a sucrose sulfate-aluminium complex that binds to the mucosa, thus creating a physical barrier that impairs diffusion of hydrochloric acid in the gastrointestinal tract and prevents degradation of mucus by acid. It also stimulates bicarbonate output and acts like an acid buffer with cytoprotective properties. Sucralfate was approved by the U.S. Food and Drug Administration (FDA) in 1981.
Mechanism of action
Sucralfate is a locally acting substance that in an acidic environment (pH < 4) reacts with hydrochloric acid in the stomach to form a cross-linking, viscous, paste-like material capable of acting as an acid buffer for as long as 6 to 8 hours after a single dose. It also attaches to proteins on the surface of ulcers, such as albumin and fibrinogen, to form stable insoluble complexes. These complexes serve as protective barriers at the ulcer surface, preventing further damage from acid, pepsin, and bile. In addition, it prevents back diffusion of hydrogen ions, and adsorbs both pepsin and bile acids. Recently, it has been indicated that sucralfate also stimulates the increase of prostaglandin E2, epidermal growth factors (EGF), bFGF, and gastric mucus.
The only FDA-approved indication for sucralfate is for the treatment of active duodenal ulcers not related to NSAID usage because the mechanism behind these ulcers is secondary to acid oversecretion. It is not technically approved for gastric ulcers because the main mechanism is not due to acid oversecretion but rather from diminished protection. The use for sucralfate in peptic ulcer disease has diminished recently, but it is still the preferred agent for stress ulcer prophylaxis.
- Active duodenal ulcer not related to NSAID use—1 g PO four times a day given 1 h before meals and at bedtime for 4–8 weeks
- Maintenance therapy for resolved duodenal ulcers—1 g PO bid on empty stomach
- Gastric ulcer not related to NSAID use and gastritis due to GERD—1 g PO four times a day 1 h before meals and at bedtime. Triple combination therapy with lansoprazole + cisapride + sucralfate can significantly improve symptoms and quality of life and was more cost-effective than ranitidine combination group.
- Aphthous ulcer and stomatitis due to radiation or chemotherapy—5-10 mL PO suspension swish and spit/swallow four times a day.
- Proctitis from radiation or ulcerative colitis—3 g/15 mL rectal suspension once or twice daily.
- Gastro-esophageal reflux disease during pregnancy -- first-line drug therapy combined with lifestyle and diet modification.
- Stress ulcer prophylaxis—The use of sucralfate rather than H2 antagonists for stress ulcer prophylaxis, and measures to prevent aspiration, such as semirecumbent positioning or continuous subglottic suctioning, have all been shown to reduce the risk of ventilator-associated pneumonia (VAP).
- Prevention of stricture formation—Sucralfate has an inhibitory effect on stricture formation in experimental corrosive burns and can be used in the treatment of corrosive esophageal burns to enhance mucosal healing and suppress stricture formation
- Rectal bleeding and its management after irradiation for uterine cervical cancer
- Grade 1 bleeding experienced immediate relief with sucrasulfate enema for 1 month.
- Grade 2 bleeding, sucrasulfate enema and/or coagulation were effective.
- Grade 3 bleeding lasted for 1 year despite frequent transfusions and coagulation.
- Grade 2 and 3 rectal bleeding occurred in 8.5% of patients. The most significant risk factor was the ICRU-CRBED. Prompt treatment with a combination of sucrasulfate enema and coagulation is effective in controlling Grade 1 and 2 rectal bleeding without the development of fistula or stricture.
DUODENAL ULCER: It is used in the short-term (up to 8 weeks) treatment of duodenal ulcer.
Antacids may be used as adjuncts to sucralfate therapy to relieve pain, but should not be taken within 30 minutes before or after administration of sucralfate.
GASTRIC ULCER: Sucralfate has been used in the treatment of patients with gastric ulcer
Prevention and treatment of chemotherapy inducedmucositis
Stress ulcer prophylaxis
Ulcer of rectum
The most common side effects seen are constipation 2-3% and bezoar formation. Less commonly reported include flatulence, cephalalgia (headache), hypophosphatemia, and xerostomia (dry mouth). Avoid using this drug in patients with chronic renal failure, it might cause them aluminum-induced nephropathy. Nursing mothers: Uncertain.
Onset: 1-2 hr (initial onset for PUD)
Absorption: <5% (PO)
Duration: Up to 6 hr due to high affinity for defective mucosa (PUD)
Bioavailability: 5% as sucralfate is considered non-systemic, sucrose octasulfate: 5%, aluminum:0.005%
Metabolism: Not metabolized, excreted unchanged in urine
Excretion: Primarily in urine as unchanged drug
- Merck Index, 12th Edition, 9049.
- Maton PN (2003). "Profile and assessment of GERD pharmacotherapy". Cleve Clin J Med. 70 Suppl 5: S51–70. doi:10.3949/ccjm.70.Suppl_5.S51. PMID 14705381.
- Jian-Min, Si; Liang-Jing, Wang; Shu-Jie, Chen; Lan, Zhao; Ning, Dai (2003). "Quality of life and cost-effectiveness of combined therapy for reflux esophagitis". Journal of Zhejiang University SCIENCE A 4 (5): 602–6. doi:10.1631/jzus.2003.0602. PMID 12958722.
- Aliment Pharmacol Ther. 2005 Nov 1;22(9):749-57.
- Respir Care. 2005 Jun;50(6):725-39; discussion 739-41.
- Surg Today. 2005;35(8):617-22.
- International Journal Radiation Oncology Biological Physics, 2004 Jan 1;58(1):98-105
- Katzung, Bertram G. Basic and Clinical Pharmacology, 9th ed. (2004).
- Medline Plus
- Medicine Net
- Rx List
- Kyoto Encyclopedia of Genes and Genomes
- Carafate prescribing information